Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working Group

By sjmartinez • November 3, 2023

Berthelsen DB, Simon LS, Ioannidis JPA, Voshaar M, Richards P, Goel N, Strand V, Nielsen SM, Shea BJ, Tugwell P, Bartlett SJ, Hazlewood GS, March L, Singh JA, Suarez-Almazor ME, Boers M, Stevens RM, Furst DE, Woodworth T, Leong A, Brooks PM, Flurey C, Christensen R; OMERACT Safety Working Group. Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working Group. Semin Arthritis Rheum. 2023 Oct 26;63:152288. doi: 10.1016/j.semarthrit.2023.152288. Epub ahead of print. PMID: 37918049.

Tags: Adverse events, Core outcome set, Harms, OMERACT, Publications, Rheumatology, rheumatology, safety

Updated Psoriasis Prevalence and Risk Factors in the United States-Insights From the 2023 NHIS

Engel P, Wu JJ. Updated Psoriasis Prevalence and Risk Factors in the United States-Insights From the 2023 NHIS. Exp Dermatol. 2025 Aug;34(8):e70146. doi: 10.1111/exd.70146. PMID:[...]

Benefits of Earlier Apremilast Initiation in Patients with Psoriasis and Limited Skin Involvement: Results from a Real-World Retrospective Study

Armstrong A, Strober B, Gisondi P, Orroth KK, Cordey M, Kent ST, Deignan C, Jardon S, Hernandez RK, Brookhart MA, Stein Gold L. Benefits of[...]

Novel Virtual Reality Intervention for Stress Reduction Among Patients With or at Risk for Cardiovascular Disease: Mixed Methods Pilot Study

Makaroff KE, Van C, Grospe V, Edmunds L, Calfon-Press MA, Watson KE, Horwich T. Novel Virtual Reality Intervention for Stress Reduction Among Patients With or[...]